- socially bharat
- September 12, 2024
Neuraptive Therapeutics Receives FDA Breakthrough Therapy Designation for NTX-001 and Provides Update on the Advancements of NTX-001 for the Treatment of Peripheral Nerve Injury Requiring Repair
Chesterbrook, Pa., United States: – Breakthrough Therapy designation for NTX-001 granted by FDA – Preparation is underway for the Phase